Elevance Health Buy Rating Boosts Target to $498 on 14.5x 2028 Earnings
Analysts upgraded Elevance Health to Buy, lifting its price target to $498 from $363 based on a 14.5x multiple of projected 2028 earnings of $34.34 per share. Broader sector upgrades reflect confidence that medical cost inflation has peaked, positioning the company for margin improvement through disciplined pricing and improved underwriting.
1. Upgrade and Target Increase
Elevance Health received a Buy rating with its price target raised to $498 from $363, marking a 37% increase based on projected earnings growth.
2. Valuation Implications
The new target implies a 14.5x multiple on projected 2028 earnings of $34.34 per share, up from under 11x previously, underscoring renewed confidence in the company's margin trajectory.
3. Margin Recovery Catalysts
Peaking medical cost inflation and stricter product pricing are expected to drive underwriting gains, while claims management enhancements should support margin expansion through 2028.